Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research38

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research38

FiltersClear all

Status

Recruiting12
Enrolling by invitation1
Active, not recruiting13
Completed8
Terminated4

Study type

Interventional38

Phase

Phase 2/338
Not reported1,641
Phase 3325
Not applicable304
Phase 2286
Phase 1103

Investigator

Ellen J Scherl2
Gail J Roboz2
Lok W. Yung2
Uqba Khan2
Arun B. Jesudian1

Show all 34Show fewer

Department

Medicine31
Pediatrics3
Neurology2
Psychiatry1
Radiation Oncology1

Condition

COVID-192
Coronavirus Infections2
Crohn Disease2
Leukemia, Myeloid, Acute2
Myelodysplastic Syndromes2

Show all 50

Intervention type

Drug31
Biological7
Procedure7
Radiation4
Device3
Other2

Sponsor type

Industry26
NIH7
Other academic5

Start date

Has results posted14

Phase 2/3×Clear all

Showing 1–20 of 38 studiesSort:

Active, not recruitingInterventional · Phase 2/3NCT02339571 ↗
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Barbara MaPI
Intervention
Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Echocardiography Test · Biological: Ipilimumab · Procedure: Magnetic Resonance Elastography · Procedure: Multigated Acquisition Scan · Biological: Nivolumab · Biological: Sargramostim

FiltersClear all

Status

Recruiting12
Enrolling by invitation1
Active, not recruiting13
Completed8
Terminated4

Study type

Interventional38

Phase

Phase 2/338
Not reported1,641
Phase 3325
Not applicable304
Phase 2286
Phase 1103

Investigator

Ellen J Scherl2
Gail J Roboz2
Lok W. Yung2
Uqba Khan2
Arun B. Jesudian1

Show all 34Show fewer

Department

Medicine31
Pediatrics3
Neurology2
Psychiatry1
Radiation Oncology1

Condition

COVID-192
Coronavirus Infections2
Crohn Disease2
Leukemia, Myeloid, Acute2
Myelodysplastic Syndromes2

Show all 50

Intervention type

Drug31
Biological7
Procedure7
Radiation4
Device3
Other2

Sponsor type

Industry26
NIH7
Other academic5

Start date

Has results posted14

Phase 2/3×Clear all

Showing 1–20 of 38 studiesSort:

Active, not recruitingInterventional · Phase 2/3NCT02339571 ↗
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Barbara MaPI
Intervention
Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Echocardiography Test · Biological: Ipilimumab · Procedure: Magnetic Resonance Elastography · Procedure: Multigated Acquisition Scan · Biological: Nivolumab · Biological: Sargramostim

Phase 1/2

Phase 454

Early phase 13

Ashish Saxena1

Alexander Ja-Ho Chou1

Hani Lamie Ashamalla1

Marianne Elizabeth Nellis1

Show fewer

Adenocarcinoma Of Esophagus1
Adenoviridae Infections1
Anemia, Refractory, with Excess of Blasts1
Carcinoma, Non-Small-Cell Lung1
Cardiomyopathy, Hypertrophic1
Clostridium Infections1
Colitis, Ulcerative1
Colonic Neoplasms1
Coronaviridae Infections1
Critical Illness1
Cytomegalovirus Infections1
Depression1
Depressive Disorder, Major1
Epstein-Barr Virus Infections1
Esophageal and Gastric Varices1
Fibrosis1
Gliosarcoma1
Hematologic Diseases1
Hemorrhage1
Hepatitis D1
Hypertension, Portal1
Leukemia1
Leukemia, Lymphocytic, Chronic, B-Cell1
Leukemia, Myelomonocytic, Chronic1
Lung Neoplasms1
Melanoma1
Neoplasms1
Nidovirales Infections1
Non-alcoholic Fatty Liver Disease1
Osteosarcoma1
Parkinson Disease1
Polycystic Kidney, Autosomal Dominant1
Polycystic liver disease1
Primary Myelofibrosis1
Pulmonary Arterial Hypertension1
Pulmonary Disease, Chronic Obstructive1
RNA Virus Infections1
Rectal Neoplasms1
Recurrence1
Rejection, Psychology1
Respiratory Distress Syndrome1
Severe Acute Respiratory Syndrome1
Suicidal Ideation1
Venous Thromboembolism1
Venous Thrombosis1

Genetic

Dates

Nov 2015 – Jun 2033 (est.)

Sponsor

ECOG-ACRIN Cancer Research Group

Stage III Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7

Active, not recruitingInterventional · Phase 2/3NCT02598661 ↗

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Pinkal DesaiPI

Intervention: Drug: Imetelstat Sodium · Drug: Placebo
Dates: Jan 2016 – Oct 2023· Results posted
Sponsor: Geron Corporation

Myelodysplastic Syndromes

RecruitingInterventional · Phase 2/3NCT03435796 ↗

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Roger N PearsePI

Intervention: Genetic: Gene-modified (GM) T cell therapy
Dates: Jul 2018 – May 2043 (est.)
Sponsor: Celgene Corporation

Neoplasms

Active, not recruitingInterventional · Phase 2/3NCT03466411 ↗

A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Ellen J ScherlPI

Intervention: Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2 · Drug: Guselkumab Dose 3 · Drug: Guselkumab Dose 4 · Drug: Guselkumab Dose 5 · Drug: Guselkumab · Drug: Ustekinumab · Drug: Placebo
Dates: Apr 2018 – Oct 2023· Results posted
Sponsor: Janssen Research & Development, LLC

Crohn's Disease

Active, not recruitingInterventional · Phase 2/3NCT03604991 ↗

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Manish A ShahPI

Intervention: Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Biological: Ipilimumab · Biological: Nivolumab · Drug: Paclitaxel · Procedure: Positron Emission Tomography · Radiation: Radiation Therapy
Dates: May 2019 – Mar 2027 (est.)
Sponsor: ECOG-ACRIN Cancer Research Group

Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8+5 more

Active, not recruitingInterventional · Phase 2/3NCT03701308 ↗

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Gail J RobozPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Cytarabine · Drug: Daunorubicin · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Drug: Uproleselan
Dates: Mar 2019 – Oct 2024· Results posted
Sponsor: Alliance for Clinical Trials in Oncology

Acute Myeloid Leukemia

Active, not recruitingInterventional · Phase 2/3NCT04150068 ↗

A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination With an Optimized Background Regimen in Heavily Treatment Experienced People Living With HIV-1 Infection With Multidrug Resistance

Sorana Segal-MaurerPI

Intervention: Drug: Oral Lenacapavir · Drug: Oral Lenacapavir Placebo · Drug: Subcutaneous Lenacapavir · Drug: Failing ARV Regimen · Drug: Optimized Background Regimen (OBR)
Dates: Nov 2019 – Oct 2020· Results posted
Sponsor: Gilead Sciences, Inc.

HIV-1-infection

RecruitingInterventional · Phase 2/3NCT04256317 ↗

A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)

Gail J RobozPI

Intervention: Drug: Azacitidine · Drug: ASTX030 (cedazuridine + azacitidine) · Drug: Cedazuridine · Drug: Venetoclax
Dates: May 2020 – Nov 2027 (est.)
Sponsor: Astex Pharmaceuticals, Inc.

Myelodysplastic SyndromesAcute Myeloid LeukemiaMyelodysplastic Syndrome/Neoplasm+1 more

Enrolling by invitationInterventional · Phase 2/3NCT04848506 ↗

A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)

Daniel McDonaldPI

Intervention: Drug: Aficamten (5 - 20 mg)
Dates: May 2021 – Mar 2029 (est.)
Sponsor: Cytokinetics, Inc.

Symptomatic Hypertrophic Cardiomyopathy (HCM)

RecruitingInterventional · Phase 2/3NCT04924322 ↗

Age-dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-associated Thrombosis in Critically Ill Children

Marianne Elizabeth NellisPI

Intervention: Drug: Enoxaparin
Dates: May 2022 – Apr 2027 (est.)
Sponsor: Yale University

Deep Venous Thrombosis

RecruitingInterventional · Phase 2/3NCT05174169 ↗

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Uqba KhanPI

Intervention: Device: Signatera test · Drug: mFOLFOX6 3-6 month · Drug: CAPOX 3 month · Drug: mFOLFIRINOX · Drug: mFOLFOX6 6 month · Drug: CAPOX 6 month
Dates: Jul 2022 – Mar 2029 (est.)
Sponsor: NRG Oncology

Stage III Colon Cancer

Active, not recruitingInterventional · Phase 2/3NCT05281328 ↗

A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Symptomatic Polycystic Liver Disease

Arun B. JesudianPI

Intervention: Drug: CAM2029 · Drug: Placebo
Dates: Jun 2022 – Feb 2025· Results posted
Sponsor: Camurus AB

Polycystic Liver Disease

Active, not recruitingInterventional · Phase 2/3NCT05312879 ↗

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease

Jay LakkisPI

Intervention: Drug: VX-147 · Drug: Placebo
Dates: Mar 2022 – Jun 2028 (est.)
Sponsor: Vertex Pharmaceuticals, Inc.

Proteinuric Kidney Disease

Active, not recruitingInterventional · Phase 2/3NCT05330182 ↗

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence

Carl V. CrawfordPI

Intervention: Drug: LMN-201 · Drug: Placebo
Dates: Aug 2024 – Aug 2026
Sponsor: Lumen Bioscience, Inc.

Clostridioides Difficile Infection

RecruitingInterventional · Phase 2/3NCT05416307 ↗

A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Justin David KanerPI

Intervention: Drug: ELA026
Dates: May 2022 – Mar 2028 (est.)
Sponsor: Electra Therapeutics INC

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Active, not recruitingInterventional · Phase 2/3NCT05502341 ↗

An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens

Lok W. YungPI

Intervention: Drug: Bictegravir · Drug: Lenacapavir · Drug: BIC/LEN FDC · Drug: Stable Baseline Regimen
Dates: Aug 2022 – Sep 2025· Results posted
Sponsor: Gilead Sciences, Inc.

HIV-1-infection

Active, not recruitingInterventional · Phase 2/3NCT05610163 ↗

The Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-free Survival in Patients With Locally Advanced Rectal Cancer

Uqba KhanPI

Intervention: Drug: Capecitabine · Drug: 5-fluorouracil · Drug: Leucovorin calcium · Drug: Irinotecan · Drug: Oxaliplatin · Radiation: Long Course Chemoradiotherapy · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Sigmoidoscopy · Procedure: biopsy
Dates: Dec 2022 – Jul 2030 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

Stage II Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8Locally Advanced Rectal Adenocarcinoma

RecruitingInterventional · Phase 2/3NCT05691478 ↗

A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Alexander Ja-Ho ChouPI

Intervention: Procedure: Bone Scan · Drug: Cabozantinib S-malate · Drug: Cisplatin · Procedure: Computed Tomography · Drug: Doxorubicin Hydrochloride · Procedure: Magnetic Resonance Imaging · Drug: Methotrexate · Procedure: Surgical Procedure · Procedure: X-Ray Imaging
Dates: Mar 2023 – Mar 2030 (est.)
Sponsor: Children's Oncology Group

High Grade OsteosarcomaLocalized OsteosarcomaMetastatic Osteosarcoma+1 more

RecruitingInterventional · Phase 2/3NCT05987241 ↗

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

Cora SternbergPI

Intervention: Procedure: Biospecimen Collection · Other: cfDNA or ctDNA Measurement · Procedure: Computed Tomography · Procedure: Cystoscopy · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Other: Questionnaire Administration · Biological: Relatlimab
Dates: Feb 2024 – Sep 2030 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

Muscle Invasive Bladder Urothelial CarcinomaMuscle Invasive Renal Pelvis Urothelial CarcinomaMuscle Invasive Ureter Urothelial Carcinoma+4 more

Active, not recruitingInterventional · Phase 2/3NCT06544733 ↗

An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1

Lok W. YungPI

Intervention: Drug: Lepetegravir · Drug: Lenacapavir pacfosacil · Drug: Placebo to Match BVY · Drug: Bictegravir/emtricitabine/tenofovir alafenamide · Drug: Lepetegravir/Lenacapavir pacfosacil FDC · Drug: Placebo to Match GS1720/GS-4182 FDC
Dates: Aug 2024 – Jan 2028 (est.)
Sponsor: Gilead Sciences, Inc.

HIV-1-Infection

‹ Prev1 2 Next ›